FDA Releases Draft GDUFA/PDUFA Reauthorization Letters, Committing to Strengthen Cell and Gene Therapy Program and Leverage Real-World Evidence

August 23, 2026

Holland & Knight USA

Overview

The U.S. FDA has released draft commitment letters for the reauthorization of the Generic Drug User Fee Amendments (GDUFA) and Prescription Drug User Fee Act (PDUFA). These letters include the FDA’s commitment to enhance staff capacity, building upon the success of the Cell and Gene Therapy Program (CGTP), to ensure timely development and delivery of next-generation CGT products to patients. The FDA also explicitly states its intention to continue leveraging Real-World Evidence (RWE) and provide annual reports on its utilization.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has published draft commitment letters for the reauthorization of the Generic Drug User Fee Amendments (GDUFA) and the Prescription Drug User Fee Act (PDUFA), outlining a clear strategy to accelerate the development and approval of cell and gene therapy (CGT) products. The letters explicitly state the FDA’s commitment to enhancing staff capacity and improving the predictability of regulatory processes, building on the success of the CGT Program (CGTP), to ensure next-generation CGT products reach patients in a timely manner. Furthermore, the FDA plans to continue utilizing Real-World Evidence (RWE) and providing annual reports, aiming to improve the overall efficiency and safety of drug development.

Technical / Clinical Details

CGTP Enhancement: Recognizing the innovative nature of CGT products and their significant medical potential, the FDA states its intention to further strengthen the infrastructure of the Cell and Gene Therapy Program (CGTP). This may include increasing the number of reviewers, deepening specialized expertise, and enhancing training to keep pace with cutting-edge scientific and technological advancements. This reinforcement aims to streamline the complex regulatory review process for CGT products, enabling developers to achieve approvals more rapidly.
Improving Regulatory Process Predictability: User Fee Acts are crucial for the FDA to secure funding to expedite drug review and improve outcomes. The current draft commitment letters specifically emphasize efforts to enhance predictability in the CGT product development pathway. This might involve providing clear guidance to developers, fostering early and frequent dialogue with the FDA, and adhering to review timelines.
Continued Utilization of Real-World Evidence (RWE): The FDA recognizes the increasing importance of RWE in drug development and regulatory decision-making, and plans to continue and expand its utilization. RWE, derived from electronic health records, claims data, patient registries, and wearable devices, complements traditional clinical data by providing insights into drug effectiveness and safety profiles across large patient populations, aiding in post-market surveillance and exploration of new indications. The FDA will ensure transparency through annual reports on RWE utilization and outcomes.
Leveraging the Sentinel Initiative: The FDA is enhancing post-market safety monitoring for drugs by utilizing large-scale electronic healthcare data networks like the Sentinel Initiative. This platform is expected to play a crucial role in rapidly identifying and evaluating the long-term safety and potential adverse effects of CGT products.

Background & Context

Cell and gene therapies are rapidly evolving as groundbreaking treatments for many intractable diseases, but their complex characteristics necessitate sophisticated regulatory review processes. The FDA’s clear articulation of strengthening the CGTP and leveraging RWE within the reauthorization process for GDUFA and PDUFA demonstrates a strong recognition of this field’s importance. This reflects the FDA’s commitment to both fostering innovation and ensuring patient safety. The industry anticipates that a more predictable and efficient approval pathway from regulatory authorities will reduce investment risks and accelerate the market introduction of new therapies.

Strategic Significance & Outlook

The content of the final GDUFA and PDUFA commitment letters will shape the direction of the FDA’s drug review activities for the coming years. Specifically, detailed information on concrete CGTP enhancements, examples of RWE-informed regulatory decisions, and their annual reports will be crucial for CGT developers, investors, and patient communities. It is expected that these FDA initiatives will further energize the pipeline for next-generation cell and gene therapy products, paving the way for faster and safer delivery of innovative treatments to patients with unmet medical needs.

Source: https://www.hklaw.com/en/insights/publications/2026/08/fda-releases-draft-gdufa-pdufa-commitment-letters-as-user-fee

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.